While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

We recently published a list of Billionaire Ken Fisher’s Top 13 Growth Stock Picks. In this article, we are going to take a ...

Vanguard Health Care ETF (VHT) is rated a hold due to high valuations and low profitability of top holdings despite strong ...

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

If  you're looking for a low-risk growth stock that also happens to be outperforming the S&P 500 (^GSPC-0.33%) so far this ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is most impactful in the drug discovery marketplace: — Goldman ...

INDIANAPOLIS: Drugmaker Eli Lilly and Company’s SVP and chief communications officer, Kathryn Beiser, has resigned. Beiser ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...